Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115647) titled 'A non-interventional, multicenter, retrospective real-world study on the treatment of mHSPC by Rilvigliam combined with ADT' on Dec. 29, 2025.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Ningbo University
Condition:
Metastatic hormone sensitive prostate cancer
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: ADT+Rezvilutamide:500;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302988
Published by HT Digital Content Services with perm...